Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial

被引:10
|
作者
Chotiyarnwong, Chayaporn [1 ,2 ]
Nair, Krishnan [2 ]
Angelini, Lorenza [3 ,4 ]
Buckley, Ellen [3 ,4 ]
Mazza, Claudia [3 ,4 ]
Heyes, Daniel [5 ]
Ramiz, Ridha [5 ]
Baster, Kathleen [6 ]
Ismail, Azza [2 ]
Das, Joyutpal [2 ]
Ali, Ali [7 ]
Lindert, Ralf [2 ]
Sharrack, Basil [2 ]
Price, Sian [2 ]
Paling, David [2 ]
机构
[1] Mahidol Univ, Rehabil Med, Fac Med, Siriraj Hosp, Bangkok, Thailand
[2] Sheffield Teaching Hosp NHS Fdn Trust, Neurosci, Sheffield, S Yorkshire, England
[3] Univ Sheffield, Dept Mech Engn, Sheffield, S Yorkshire, England
[4] Univ Sheffield, INSIGNEO, Sheffield, S Yorkshire, England
[5] Univ Sheffield, SiTRAN, Sheffield, S Yorkshire, England
[6] Univ Sheffield, Stat Serv Unit, Sheffield, S Yorkshire, England
[7] Sheffield Teaching Hosp NHS Fdn Trust, NIHR Sheffield Biomed Res Ctr, Sheffield, S Yorkshire, England
关键词
multiple sclerosis; remote ischemic preconditioning; fatigue; gait; exercise tolerance; EXERCISE CAPACITY; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; PERFORMANCE; RELIABILITY; PROTECTION;
D O I
10.1136/bmjno-2019-000022
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals. Objective This study aimed to assess the effect of RIPC on walking in people with multiple sclerosis (MS). Methods This was a double-blind randomised controlled clinical trial. We used three cycles of RIPC delivered by occluding the upper arm with a blood pressure (BP) cuff inflated to a pressure of 30 mm Hg above the systolic BP. In patients in the sham intervention group, the BP cuff was inflated only to 30 mm Hg below diastolic BP. Outcome measures included the Six-Minute Walk Test (6MWT), gait speed, the Borg rate of perceived exertion (RPE) scale, the tolerability of the RIPC using a Numerical Rating Scale for discomfort from 0 to 10, and adverse events. We identified responders meeting the minimal clinically important difference (MCID) established in the literature in each group. Results Seventy-five participants completed the study (RIPC: 38 and Sham: 37). The distance walked during the 6MWT improved by 1.9% in the sham group and 5.7% in the RIPC group (p=0.012). The number of responders meeting MCID criteria in the RIPC group was significantly greater compared with the sham intervention group. No serious adverse events occurred. Conclusion Single cycle of RIPC resulted in immediate improvement in walking distances during 6MWT in people with MS.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Can Remote Ischaemic Preconditioning improve walking in people with Multiple Sclerosis?
    Buckley, Ellen
    van Gelder, Linda
    Abu Baker, Mohamad Amin Mohamed
    Baster, Kathleen
    Brittain, Gavin
    Paling, David
    Sharrack, Basil
    Mazza, Claudia
    Nair, Siva
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 675 - 675
  • [2] Randomised sham-controlled double-blind trial evaluating remote ischaemic preconditioning in solid organ transplantation: a study protocol for the RIPTRANS trial
    Uutela, Aki
    Helantera, Ilkka
    Lemstrom, Karl
    Passov, Arie
    Syrjala, Simo
    Aberg, Fredrik
    Makisalo, Heikki
    Nordin, Arno
    Lempinen, Marko
    Sallinen, Ville
    BMJ OPEN, 2020, 10 (11):
  • [3] Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial
    Hughes, C. M.
    Smyth, S.
    Lowe-Strong, A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (11) : 1229 - 1338
  • [4] Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
    Hartung, HP
    Gonsette, R
    König, N
    Kwiecinski, H
    Guseo, A
    Morrissey, SP
    Krapf, H
    Zwingers, T
    LANCET, 2002, 360 (9350): : 2018 - 2025
  • [5] Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Goodman, Andrew D.
    Brown, Theodore R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Schwid, Steven R.
    Cohen, Ron
    Marinucci, Lawrence N.
    Blight, Andrew R.
    LANCET, 2009, 373 (9665): : 732 - 738
  • [6] Neuromuscular Electrical Stimulation Improves Walking Performance In People With Multiple Sclerosis: Double-blind, Randomized Trial
    Almuklass, Awad M.
    Davis, Leah
    Hamilton, Landon
    Hebert, Jeffrey R.
    Alvarez, Enrique
    Enoka, Roger M.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2017, 49 (05): : 632 - 632
  • [7] Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis - a randomised, double-blind controlled trial
    Piatkowski, J.
    Kern, S.
    Ziemssen, T.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S255 - S256
  • [8] Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial
    Thielmann, Matthias
    Kottenberg, Eva
    Kleinbongard, Petra
    Wendt, Daniel
    Gedik, Nilguen
    Pasa, Susanne
    Price, Vivien
    Tsagakis, Konstantinos
    Neuhaeuser, Markus
    Peters, Juergen
    Jakob, Heinz
    Heusch, Gerd
    LANCET, 2013, 382 (9892): : 597 - 604
  • [9] Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
    Green, Ari J.
    Gelfand, Jeffrey M.
    Cree, Bruce A.
    Bevan, Carolyn
    Boscardin, W. John
    Mei, Feng
    Inman, Justin
    Arnow, Sam
    Devereux, Michael
    Abounasr, Aya
    Nobuta, Hiroko
    Zhu, Alyssa
    Friessen, Matt
    Gerona, Roy
    von Budingen, Hans Christian
    Henry, Roland G.
    Hauser, Stephen L.
    Chan, Jonah R.
    LANCET, 2017, 390 (10111): : 2481 - 2489
  • [10] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
    Kappos, Ludwig
    Hartung, Hans-Peter
    Freedman, Mark S.
    Boyko, Alexey
    Radue, Ernst Wilhelm
    Mikol, Daniel D.
    Lamarine, Marc
    Hyvert, Yann
    Freudensprung, Ulrich
    Plitz, Thomas
    van Beek, Johan
    LANCET NEUROLOGY, 2014, 13 (04): : 353 - 363